On average, people with schizophrenia die 20–25 years sooner than those without schizophrenia. How can we spot metabolic side effects early in our patients, and what should we be looking for exactly?

Several studies are discussed in this podcast, including one that suggests modest clinical utility for short-term use of melatonin in children and adolescents struggling with sleep-onset insomnia.

A recent study that explored long-term treatment outcomes for children with OCD is discussed with a bonus CME test.

Drew Ramsey, MD, talks about new research behind nutritional psychiatry. At the end there’s going to be a test. That’s right – a real CME test so you can start earning credits directly from the podcast.

How does schizophrenia differ between men and women? And are there adjunctive treatments that can improve outcomes for female patients with schizophrenia?

Aducanumab (Aduhelm) just got FDA approval in dementia, but many experts think it should not have passed the finish line. We interviewed Peter Whitehouse, professor of neurology at Case Western Reserve University and author of American Dementia, on what went...

Patients with repeated deliberate foreign body ingestion (DFBI) are among the most challenging we see. In any given room, there’s bound to be some small object that can be swallowed. So how can we reduce the likelihood of foreign body...

Clinicians explore what to do if your patient just has mania and doesn’t tend to have much trouble with depression.

What distinguishes Kloxxado from the many other ways naloxone is delivered and why was it developed in the first place?

In the final episode of our 3-part series on antipsychotics, you’re going to find out whether these drugs have a class effect in mania, among other topics that inform practice.